Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
Completed enrollment of patient expansion cohort of 20 patients at the RP2D of 4 mg/kg…
News
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
Completed enrollment of patient expansion cohort of 20 patients at the RP2D of 4 mg/kg…
AltruBio Announces FDA Clearance of IND Application for Immune Checkpoint Enhancer ALTB-268 to initiate a Phase 2 Clinical Trial for the Treatment of Ulcerative Colitis
Global multi-arm Phase 2 clinical trial expected to launch in 2024 SAN FRANCISCO, Sept. 26,…
AltruBio Announces FDA Clearance of IND Application for Immune Checkpoint Enhancer ALTB-268 to initiate a Phase 2 Clinical Trial for the Treatment of Ulcerative Colitis
Global multi-arm Phase 2 clinical trial expected to launch in 2024 SAN FRANCISCO, Sept. 26,…
electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
Acasti Announces $7.5 Million Private Placement Equity Financing
PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or…
FDA Accepts Defender Pharmaceuticals’ New Drug Application for Intranasal Scopolamine Gel
PDUFA date of January 26th, 2024 Assigned Priority Review Status at the Request of the…
Enable Announces Rebate Strategist Awards to Recognize its Customer Pioneers in Rebate Management
SAN FRANCISCO–(BUSINESS WIRE)–#AndrewButt—Enable, the leading rebate management platform, announced today its first-ever Rebate Strategist Awards…
Axial Therapeutics Announces Completion of Enrollment in Global Phase 2b Clinical Trial for AB-2004 for Irritability Associated with Autism
– Topline clinical data anticipated in 1Q 2024 – – First-in-class small molecule therapeutic targets…
Ring Therapeutics Announces Two Late Breaker Presentations at the 30th Annual European Society of Gene & Cell Therapy Conference
Ring to present new data on its Anellogy™ platform The first new class of viral…
Recce Pharmaceuticals Completes Dosing in Phase I/II Clinical Trial of RECCE® 327 for Urinary Tract Infections
Cohort dosing complete in healthy subjects, with the Phase I/II study on track to meet…
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
Proposed all-cash acquisition will materially expand Alfasigma’s portfolio in gastroenterology and hepatology and its presence…
BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease
Expects to announce topline data expected in the November/December timeframe. Enrolled patients had underlying medical…
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
Initial data suggests 12-month survival is consistent with an increased tail on the maturing survival…
IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City
Management presentations will highlight IN8bio’s clinical and scientific programs, including upcoming data releases at several…
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
Figure 1. Treatment with pepinemab in combination with KEYTRUDA appears to induce formation of highly…
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes
GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical…
Ovid Therapeutics to Host Investor Event – R&D Day on Monday, October 2, 2023
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical…
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
CLEVELAND, Sept. 26, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the…
Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova
Proposed acquisition adds market leading magnetic mixing technology for upstream and downstream bioprocess applications Expands Repligen’s Fluid Management portfolio,…